February 20, 2024
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2023 After Market Close on February 26, 2024
November 6, 2023
Revolution Medicines Reports Third Quarter 2023 Financial Results and Update on Corporate Progress
November 1, 2023
Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Revolution Medicines Stockholders Vote “FOR” Proposed Acquisition of EQRx, Inc.
October 31, 2023
Revolution Medicines to Report Financial Results for Third Quarter 2023 After Market Close on November 6, 2023
October 22, 2023
Revolution Medicines Presents Promising Clinical Activity and Safety Data from Phase 1/1b Trial of RMC-6236
Displaying 11 - 20 of 134